MedMira Becomes an Approved Supplier to the Pan American Health Organization (PAHO)

    Initial PAHO Order is a Gateway to Latin American Market Opportunities

    HALIFAX, April 2 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a global market leader in premium rapid diagnostic solutions,
announced today that it is now an approved supplier to the Pan American Health
Organization (PAHO) and has received an initial purchase order for rapid HIV
tests from the Ministry of Health in Belize. The PAHO, headquartered in
Washington, D.C., with 35 member states, is an international public health
agency working with Latin America and Caribbean countries on priority health
issues such as HIV. It also serves as the regional office for the World Health
Organization (WHO) in the Americas.
    "This initial PAHO order for Belize is an important milestone in building
MedMira's reputation as a quality supplier of rapid tests for Latin American
and Caribbean countries and a gateway for future revenue opportunities in
larger markets like Brazil and Venezuela," said Hermes Chan, President & CEO,
MedMira Inc. "Being recognized as an approved supplier by the PAHO will
facilitate further growth for us in the region with our Multiplo line of rapid
tests and ease some of the challenges and complexities inherent in doing
business in the Latin American market."
    The MedMira rapid HIV tests purchased by the PAHO for the Ministry of
Health in Belize will be used for testing at the point of care, as well as in
the laboratory as part of an HIV/AIDS prevention program underway in the
country.
    Chan continued, "Many other organizations working in Latin America
routinely refer to PAHO vendor lists for procurement of products outside of
the PAHO programs and being an approved PAHO vendor is sometimes a requirement
for other tender opportunities."

    To learn more about the PAHO visit www.paho.org

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals around the world with reliable, rapid diagnosis for diseases such
as HIV and hepatitis C in just three minutes. The company's tests are sold
under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in
global markets. MedMira's rapid HIV test is the only one in the world to
achieve regulatory approvals in Canada, the United States, China and the
European Union.
    In January 2006, MedMira launched the Maple Biosciences division to
develop and commercialize diagnostic instruments based on two revolutionary
biosensor-based technology platforms. The solutions developed by Maple
Biosciences will enable routine laboratory tests to be performed in a matter
of minutes, increasing laboratory automation, streamlining the diagnosis of
multiple conditions and diseases and positioning MedMira to be a leading
participant in the emerging fields of personalized medicine and molecular
diagnostics. For more information visit www.maplebio.com.
    MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada with a representative office in China. Maples
Biosciences' labs are located in Toronto, Ontario. For more information visit
MedMira's website at www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E

For further information: Dr. James Smith, Investor Relations & Corporate

Affairs, (902) 450-1588, ir@medmira.com